



## OPEN ACCESS

## EDITED BY

Kathrin S. Michelsen,  
Cedars Sinai Medical Center, United States

## REVIEWED BY

Ata Ur Rehman,  
Duke University, United States  
Yu-Jen Wang,  
China Medical University, Taiwan

## \*CORRESPONDENCE

Sandra Helena Poliselli Farsky  
✉ sfarsky@usp.br

RECEIVED 04 August 2025

ACCEPTED 17 September 2025

PUBLISHED 03 October 2025

## CITATION

Filippi Xavier L, Gacesa R,  
da Rocha GHO, Broering MF, Scharf P,  
Lima FS, Faber KN, Harmsen H, Hoffmann C  
and Farsky SHP (2025) Annexin A1 levels  
affect microbiota in health and DSS-induced  
colitis/inflammatory bowel disease  
development.  
*Front. Immunol.* 16:1679071.  
doi: 10.3389/fimmu.2025.1679071

## COPYRIGHT

© 2025 Filippi Xavier, Gacesa, da Rocha,  
Broering, Scharf, Lima, Faber, Harmsen,  
Hoffmann and Farsky. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Annexin A1 levels affect microbiota in health and DSS-induced colitis/inflammatory bowel disease development

Luana Filippi Xavier<sup>1</sup>, Ranko Gacesa<sup>2,3</sup>,  
Gustavo Henrique Oliveira da Rocha<sup>4</sup>, Milena Fronza Broering<sup>1</sup>,  
Pablo Scharf<sup>1</sup>, Fabiana da Silva Lima<sup>5</sup>, Klaas Nico Faber<sup>2</sup>,  
Hermie Harmsen<sup>6</sup>, Christian Hoffmann<sup>5</sup> and  
Sandra Helena Poliselli Farsky<sup>1\*</sup>

<sup>1</sup>Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil, <sup>2</sup>Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands, <sup>3</sup>Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, <sup>4</sup>Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany, <sup>5</sup>Department of Food and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil, <sup>6</sup>Department of Medical Microbiology, University Medical Center Groningen, Groningen, Netherlands

**Background:** Inflammatory Bowel Diseases (IBDs) are characterized by intestinal dysbiosis and immune dysregulation. Annexin A1 (AnxA1) promotes epithelial repair and inhibits immune responses during IBD. However, AnxA1's impact on gut microbiota during IBD remains unclear. Here, we experimentally investigated the microbiota profile during colitis in wild-type (WT) and AnxA1-deficient mice (AnxA1<sup>-/-</sup>), and evaluated an observational cohort in IBD patients with high or low AnxA1 expression.

**Methods:** Colitis was induced in C57BL/6 WT and AnxA1<sup>-/-</sup> mice via oral administration of 2% DSS for six days. Fecal samples were collected at baseline, peak inflammation (day 6), and during the recovery phase (day 10) for 16S rRNA sequencing. Human microbiota data from the Lifelines Dutch Microbiome Project cohort, including IBD and healthy subjects, were analyzed for AnxA1 expression using R software.

**Results:** Healthy AnxA1<sup>-/-</sup> mice exhibited reduced microbial richness and a distinct gut microbiota composition, marked by increased *Proteobacteria* and *Parasutterella*, and reduced *Deferribacterota*, *Campylobacterota*, and *Verrucomicrobiota*. During DSS-induced colitis, AnxA1<sup>-/-</sup> mice showed greater weight loss and heightened inflammation, displaying earlier and more pronounced microbial shifts, including increased *Proteobacteria*, *Cyanobacteria*, *Parabacteroides*, *Bacteroides*, and *Escherichia-Shigella*. In contrast, WT mice exhibited delayed changes, with expansion of *Alloprevotella*, *Akkermansia*, and *Faecalibaculum* after day 6. In human IBD samples, Crohn's disease (CD) patients with low AnxA1 expression and active inflammation presented an altered microbiota enriched in *Lachnoclostridium* and *Parabacteroides*, while ulcerative colitis (UC) patients showed phylum-level shifts modulated by AnxA1 levels. Notably, non-inflamed CD and UC patients with low AnxA1 differed significantly in microbiota composition. Moreover, inflamed CD patients with high AnxA1

expression showed microbial profiles resembling those of healthy controls, while low AnxA1 expression was associated with a more pronounced dysbiotic state.

**Conclusion:** AnxA1 is implicated in microbiota control under healthy and IBD conditions. Accordingly, the microbiota of healthy AnxA1<sup>-/-</sup> mice, colitic AnxA1<sup>-/-</sup> mice, and IBD patients with low AnxA1 expression exhibit dysbiosis compared to their respective controls. Together, these unprecedented findings reveal AnxA1 as a potential regulatory protein in the immune–microbiota axis involved in IBD pathogenesis.

#### KEYWORDS

**ANXA1, microbiota, DSS-induced colitis, Crohn's disease, ulcerative colitis, 16S, metagenomics**

## 1 Introduction

Inflammatory Bowel Diseases (IBDs), encompassing ulcerative colitis (UC) and Crohn's disease (CD), are complex disorders influenced by genetic, environmental, and microbial factors. Clinically, IBD symptoms often include diarrhea, abdominal pain, rectal bleeding, and weight loss, with an increased risk of colorectal cancer (1–6). Diagnosis and monitoring rely on invasive procedures such as endoscopy and biopsy, underscoring the need for non-invasive biomarkers to enhance clinical management (7, 8). Treatments range from lifestyle changes and conventional anti-inflammatory drugs to advanced TNF- $\alpha$ , IL-12/IL-23, JAK and integrin inhibitors, as well as surgical procedures (9). However, many patients still experience non-responsiveness or relapse, reinforcing the need for continued research into the multifaceted mechanisms underlying IBDs (10, 11).

Alterations in mucosal integrity and gut microbial composition play a critical role in the progression of IBDs. Patients with IBD exhibit a state of dysbiosis, primarily characterized by reduced microbial diversity and depletion of beneficial phyla such as *Firmicutes* and *Bacteroidetes*, along with an expansion of potentially pathogenic phyla like *Proteobacteria* and *Actinobacteriota* (12, 13). Notably, commensal butyrate-producing bacteria that support mucosal homeostasis and exert anti-inflammatory effects, such as *Faecalibacterium prausnitzii* and *Roseburia* spp. are significantly diminished. In contrast, the abundance of pathobionts, including *Escherichia coli* (adherent-invasive strains), was markedly increased (14–17). This microbial imbalance contributes to a reduction in the production of short-chain fatty acids (SCFAs), particularly butyrate (18), which are essential for maintaining microbial diversity, epithelial integrity, and host–microbiota metabolic balance (19).

Annexin A1 (AnxA1) is a 37 kDa endogenous anti-inflammatory protein expressed by neutrophils, monocytes, macrophages, epithelial and cancer cells (20–22). AnxA1 synthesis and release are induced by glucocorticoids and inflammatory mediators. It is found in the cytosol, associated with the plasma membrane or endosomal vesicles, and released via exocytosis or through microvesicles and

exosomes (23, 24). Under stress or disease conditions, intracellular AnxA1 can translocate to the nucleus, potentially influencing gene regulation, and also interact with the cytoskeleton, modulating actin and microtubule reorganization (25–28). Secreted AnxA1 undergoes calcium-dependent conformational changes and phosphorylation, exposing its N-terminal domain responsible for its biological activities. Once phosphorylated, AnxA1 binds to membrane phospholipids and to formyl peptide receptors (FPRs), members of the G protein-coupled receptors, and controls inflammation and wound healing (24, 29, 30). Its functions include inhibition of phospholipase A2, neutrophil surveillance, inhibition of leukocyte trafficking into tissues, secretion of chemical mediators, induction of macrophage polarization and efferocytosis and epithelial cell proliferation, adhesion and migration during tissue repair (21, 31, 32). The AnxA1/FPRs' roles in the development and resolution of inflammation and tissue repair have been extensively studied in IBD experimental and clinical research. In experimental models, AnxA1-deficient mice exhibit exacerbated and non-resolving colitis. In human studies, AnxA1 is highly expressed in inflamed intestinal tissue of IBD patients (21, 33–35).

Understanding AnxA1's multifunctionality has driven therapeutic strategies, with recent studies indicating that targeting the AnxA1/FPRs pathways may reduce inflammatory disease severity and aid tissue regeneration. Indeed, genetic deficiency of AnxA1 impaired the therapeutic effects of the monoclonal antibody anti-TNF- $\alpha$  or pioglitazone in mice. In contrast, clinical observations in Crohn's disease patients revealed that those treated with anti-TNF- $\alpha$  who experienced relapse showed lower expression of AnxA1 and FPRs in the inflamed epithelium (33, 36, 37). Emerging nanoparticle-based therapies using AnxA1-mimetic peptides are also being explored to deliver drugs into the inflamed zone, stabilize the intestinal barrier, and promote tissue repair, offering new perspectives in personalized IBD treatment (38–41).

Although the role of AnxA1 in IBD is well recognized, no studies to date have characterized the microbiota profile in the absence of AnxA1, nor the microbial dynamics during IBD development under AnxA1-deficient conditions. To address this,

we analyzed the microbiota of wild-type (WT) or *AnxA1*<sup>-/-</sup> mice in a DSS-induced colitis model and evaluated a cohort of human IBD patients to identify key differences in microbiota profiles associated with the absence or impaired function of *AnxA1*.

## 2 Materials and methods

### 2.1 Animals

Male C57BL/6NCrl wild-type (WT) and Annexin A1-deficient (*AnxA1*<sup>-/-</sup>) mice aged 7–8 weeks and weighing 20–25 g were obtained from the Animal Facility of the School of Medicine at UNIFESP. Mice had conventional sanitary standards and were kept in barrier conditions on a 12-hour light/dark cycle at temperatures between 20 and 25°C with free access to water and food. All procedures were performed following the Ethical Principles for Animal Experimentation by the National Council for Animal Experimentation Control (CONCEA). The protocol of the study was approved by the Ethics Committee of Animal Use of the Faculty of Pharmaceutical Sciences of the University of São Paulo (CEUA/FCF/USP, protocol n° 617) and the Internal Biosafety Commission (CIBio).

### 2.2 Experimental colitis induced by dextran sulfate sodium

To induce experimental colitis, 2% dextran sulfate sodium (DSS; MW 40,000, Dextran Products Limited, Ontario, Canada) was administered in the drinking water for six consecutive days (days 0–6), while control animals received only filtered water. Wild-type (WT) and *AnxA1*<sup>-/-</sup> mice were divided into two groups: DSS-treated and control, and the experimental protocol lasted 10 days in total (Supplementary Figure 1A).

### 2.3 Assessment of colitis clinical score and FACS

Colitis development was monitored daily by body weight measures, in which the progression was expressed as the difference between initial and final weight, as percentage. On day 10 of the experiment, animals were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) via intraperitoneal injection. A surgical incision was made in the mice's abdominal region and the colon was removed from the ileocecal junction to the anus, washed with an isotonic solution and the organ was fragmented for FACS analysis. Intestinal tissue was subjected to enzymatic digestion with collagenase, filtered through a 40 µm strainer, and washed with PBS. After centrifugation, cells were resuspended in FACS buffer (PBS, 5% FBS, 0.02% NaN<sub>3</sub>) and incubated on ice for 15 min to block nonspecific binding (42). Cells were stained with anti-Ly6G (1:50, BD Biosciences), anti-F4/80 (1:100, eBioscience), anti-CD3e (1:50, eBioscience) and anti-CD4 (1:100, Biolegend) antibodies. Analyses were performed on a BD Accuri C6 Plus cytometer and analyzed using BD Accuri C6 software.

### 2.4 Experimental statistical analyses

All results were subjected to normality tests, including D'Agostino-Pearson and Kolmogorov-Smirnov. Clinical analyses were evaluated using Two-way ANOVA, followed by Tukey's post-test, with results expressed as mean ± standard deviation. Tissue analyses were performed using One-way ANOVA with Tukey's post-test and expressed as mean ± standard deviation. Values of *p* < 0.05 were considered significant. Statistical analyses were performed using GraphPad Prism version 8.0 (GraphPad Software, San Diego, CA, USA).

### 2.5 DNA sequencing of fecal mice samples

Feces were harvested on days 0, 6 and 10 of the experiment for 16S sequencing of the intestinal microbiota. DNA was extracted from the feces using the DNeasy Power Soil Kit (Qiagen) and Power Soil Pro Kit (Qiagen). The V4 region of the 16S ribosomal gene was amplified using the AccuPrime<sup>TM</sup> Taq DNA Polymerase System (Invitrogen), using the primers 515F–806R, as described by Caporaso et al. (43) and protocolized in the Earth Microbiome Project. Genetic material was purified using beads via the Beckman Coulter Agencourt AMPure XP Kit (Beckman Coulter), and quality and size were checked by gel electrophoresis. DNA quantification was performed using the Quant-iT PicoGreen dsDNA Kit (Invitrogen). Sequencing was performed on the Illumina MiSeq<sup>®</sup> System (Illumina INC, San Diego, CA, USA) at the Research Support Facilities Center (CEFAP) - ICB-USP, following the manufacturer's protocol, using the Illumina V2 500-cycle kit (Illumina).

### 2.6 Experimental bioinformatics analyses

Bioinformatics analyses were performed using the QIIME2 software version 2022.2. Sequences were imported into the program and demultiplexed to associate indexes with their respective samples. A total of 5,011,692 sequences were obtained, with an average of 27,998 sequences per sample. The sequences were processed through the Dada2 pipeline to filter low-quality sequences, singletons, chimeric sequences, and to dereplicate sequences to reduce repetition. The first 10 bases of the sequence were trimmed, and sequences were truncated at base 248 based on data quality scores. Results were tables of Amplicon Sequence Variants (ASVs), containing information about the frequency and sequence of ASVs in the samples. After quality control with Dada2, 3,888,180 sequences were obtained across all samples, resulting in 1,574 ASVs. Diversity and taxonomy analyses were then performed, using a sampling depth of 10,367. The ASVs were aligned using the mafft pipeline and used to build phylogeny with fast tree. Alpha diversity was assessed using Faith and Evenness metrics with statistical analysis by Kruskal-Wallis, while beta diversity was analyzed using UniFrac weighted and unweighted, with PERMANOVA and principal coordinate analysis (PCoA).

Taxonomy analysis was performed using the q2-feature-classifier pipeline with Silva database (silva-138-99-nb-weighted-classifier). All analyses were performed using rarefied tables subsampled to 10,367 sequences per sample.

## 2.7 Patient cohort and ethics committee

The data used for bioinformatics analyses in humans originates from the Lifelines Dutch Microbiome Project (DMP) cohort, a multidisciplinary prospective study designed to monitor health and health-related behaviors in 167,729 individuals living in the northern Netherlands. For this study, data from a total of 882 individuals were analyzed, including 458 individuals with Crohn's disease, 363 with ulcerative colitis, and 61 controls. The IBD patients were further subdivided based on the presence or absence of biopsy tissue inflammation and the expression level of the AnxA1 protein (high vs. normal-low). The Lifelines study was approved by the ethics committee of the University of Groningen under the protocol number METc: 2017/152. The data can be accessed and/or requested through the following website: <https://ega-archive.org/studies/EGAS00001005027>.

## 2.8 Human cohort bioinformatics analyses

The bioinformatics analyses for the translational component were performed using the R software, version 4.3.1. Pre-normalized text files containing sample counts were provided for use in the study. For alpha diversity analysis, a minimum filter of 50 counts per genus was applied. The Vegan package was used to calculate Shannon, Richness, Evenness, and Chao1 metrics. Normality was tested using the Shapiro-Wilk test, and statistical differences were analyzed using the Kruskal-Wallis test followed by Dunn's *post hoc* test. For beta diversity analysis, a filter of 50 counts per genus was applied, and the relative abundance of each genus within each sample was calculated. Using the Vegan package, Bray-Curtis distance was computed, and PERMANOVA was used for statistical analyses, with pairwise comparisons conducted using the Pairwise package. For the taxonomic analysis, the data were transformed into relative abundance and visualized using the ggplot2 package.

# 3 Results

## 3.1 The deficiency of AnxA1 influences the gut microbiota of healthy mice

Healthy AnxA1<sup>-/-</sup> mice exhibited a distinct gut microbiota profile compared to the WT mice. Beta diversity analysis at day 0 revealed a significant difference between groups (Figure 1A). Regarding alpha diversity, AnxA1<sup>-/-</sup> mice showed reduced ASV richness, while evenness did not differ between groups (Figure 1B).

In AnxA1<sup>-/-</sup> mice, a higher prevalence of the phylum *Proteobacteria* was observed, while *Deferribacterota*, *Campylobacterota*, and *Verrucomicrobiota* were reduced compared to the WT group (Figure 1C). Within these phyla, AnxA1<sup>-/-</sup> mice exhibited higher abundance of *Parasutterella* (a member of *Proteobacteria*), along with decreased abundance in *Helicobacter* (a member of *Campylobacterota*) and *Mucispirillum* (a member of *Deferribacterota*) compared to WT mice (Figure 2B).

The main genera found in both mouse strains are presented in Figure 2A. In the absence of AnxA1, significant differences were also observed in less abundant genera. For instance, *Odoribacter* and *Lactobacillus* were more abundant in AnxA1<sup>-/-</sup> mice, whereas *Prevotellaceae* UCG-001 was less abundant compared to WT. Notably, *Alloprevotella* was detected exclusively in WT mice (Figure 2B). The primary differences in genus level in healthy animals are visualized in the heatmap in Figure 2C.

FACS analysis of the colon revealed that in healthy conditions, WT and AnxA1<sup>-/-</sup> mice showed similar percentages of colonic Ly6G<sup>+</sup> neutrophils, F4/80<sup>+</sup> macrophages, and CD3<sup>+</sup> T lymphocytes (Supplementary Figure 1B).

## 3.2 Microbiota exhibits pronounced inflammatory profile in AnxA1<sup>-/-</sup> mice during colitis development

Between days 6 and 10 of DSS-induced colitis, all treated groups showed significant weight loss compared to controls, with AnxA1<sup>-/-</sup> DSS mice exhibiting greater loss on days 6 to 8 (Supplementary Figure 1C), suggesting a more severe inflammatory response in the absence of AnxA1, consistent with previous studies (33, 36, 37). During colitis, AnxA1<sup>-/-</sup> mice exhibited a marked increase in Ly6G<sup>+</sup> neutrophils and reduced influx of F4/80<sup>+</sup> macrophages compared to WT. The percentage of CD3<sup>+</sup> T cells declined in AnxA1<sup>-/-</sup> mice during inflammation, while remaining stable in WT. Interestingly, CD4<sup>+</sup> T cells were more abundant in healthy AnxA1<sup>-/-</sup> mice, but this population significantly decreased during colitis, whereas it remained unchanged in WT animals (Supplementary Figure 1B).

Day 6 of the model corresponds to the peak of clinical manifestations, while day 10 marks the recovery phase of the disease. As observed under healthy conditions, the bacteria composing the gut microbiota during experimental colitis maintain an individual pattern in the presence or absence of AnxA1 (Figure 3A). No differences in richness or evenness of the ASVs were detected between the groups through the colitis (Figure 3B).

The most abundant phyla in both groups remained *Bacteroidota* and *Firmicutes* before and after inducing colitis. However, the abundance of *Firmicutes* was increased in AnxA1<sup>-/-</sup> compared to WT on the 10th day (Figure 3C). Although AnxA1<sup>-/-</sup> maintained higher abundance of *Proteobacteria* in the peak of inflammation, this difference between groups lost significance on day 10 though (Figure 3D). *Deferribacterota* and *Campylobacterota* phyla were less abundant in AnxA1<sup>-/-</sup> mice on day 0, with slight variation on day 6 and 10. In contrast, WT mice lost abundance of this phylum through the development of the disease, so no more differences were observed






FIGURE 1

Microbiota shifts in the absence of AnxA1 in basal conditions (Day 0). (A) UniFrac weighted metric for beta diversity comparing WT and AnxA1<sup>-/-</sup> mice. P-value: 0.001 (B) Alpha diversity comparing WT and AnxA1<sup>-/-</sup> mice performing Richness (upper graph; p-value: 0.002) and Evenness (bottom graph; p-value: 0.343) metrics. (C) Relative abundance of phyla between WT and AnxA1<sup>-/-</sup> mice. ASVs tested with Mann-Whitney. *Proteobacteria*, *Deferribacterota* and *Campilobacterota* p-values <0.001, while *Verrucomicrobiota*: 0.001. n= WT: 23 and AnxA1<sup>-/-</sup>: 28. For all analyses, p-values <0.05 were considered statistically significant.

between the two groups over the days (Figures 3E, F). *Verrucomicrobiota* bacteria were increased in both groups with colitis, although lower abundance of these bacteria was observed in AnxA1<sup>-/-</sup> mice in the beginning, and on the 10<sup>th</sup>, these differences

disappeared (Figure 3G). The changes in the microbiota phyla profile through colitis can be observed in Figure 3H.

The genera *Lachnospiraceae* NK4A136 and *Bacteroides* increased on day 10, overlapping the prevalence of *Muribaculaceae* in the




FIGURE 2

Genera shifts in the absence of AnxA1 in basal conditions (Day 0). **(A)** Percentage graph of the main genera commonly found in WT and AnxA1<sup>-/-</sup> mice. **(B)** Relative abundance of genera between WT and AnxA1<sup>-/-</sup> mice. ASVs tested with Mann-Whitney. *Mucispirillum*, *Alloprevotella*, *Prevotellaceae UCG-001*, *Helicobacter* and *Parasutterella* p-values < 0.001. *Lactobacillus* p-value: 0.030 and *Odoribacter*: 0.0002. **(C)** Heatmap with the main shifts in genus level between WT and AnxA1<sup>-/-</sup> mice. *n* = WT: 23 and AnxA1<sup>-/-</sup>: 28. For all analyses, p-values < 0.05 were considered statistically significant.

AnxA1<sup>-/-</sup> animals (Figure 4A), while *Alloprevotella* continued to be identified only in WT mice (Figure 4B). The genus *Parasutterella*, more abundant at the beginning of the disease, increased in abundance on the peak of inflammation and decreased on the 10th day; no differences were observed in WT DSS mice (Figure 4C). The shift in abundance at the genus level across the days can be observed in the heatmap in Figure 4D.

### 3.3 AnxA1<sup>-/-</sup> mice are more susceptible to changes in microbiota during experimental colitis

The microbiota of WT mice started to meaningfully change from a healthy condition after the 6<sup>th</sup> day of the disease, as shown in Figure 5A. In contrast, in the absence of AnxA1,





FIGURE 3

Microbiota shifts during DSS-induced colitis between WT and AnxA1<sup>-/-</sup> mice. **(A)** UniFrac weighted metric for beta diversity comparing WT and AnxA1<sup>-/-</sup> mice through the colitis model. P-value day 0 and 6 = 0.001, day 10 = 0.003. **(B)** Alpha diversity comparing WT and AnxA1<sup>-/-</sup> mice performing Richness (upper graph; p-values day 0 = 0.002, day 6 = 0.308 and day 10 = 0.339) and Evenness (bottom graph; p-values day 0 = 0.343, day 6 = 0.064 and day 10 = 0.145) metrics. **(C–G)** Relative abundance of phyla between WT and AnxA1<sup>-/-</sup> mice. ASVs were tested with Mann-Whitney. **(H)** Relative abundance shifts for all phyla through the colitis model. *n* day 0 WT = 23 and AnxA1<sup>-/-</sup> = 28; *n* day 6 WT = 5 and AnxA1<sup>-/-</sup> = 14; *n* day 10 WT = 14 and AnxA1<sup>-/-</sup> = 16. For all analyses, p-values <0.05 were considered statistically significant.

differences in microbial diversity were already observed on day 6 (Figure 5B).

In WT mice, the most notable shifts were increments in *Turicibacter*, *Alloprevotella*, *Akkermansia*, *Bacteroides*, and *Faecalibaculum* genera. Modifications detected in lesser pronounced genus levels are presented in Figure 5C.

In contrast, AnxA1<sup>-/-</sup> mice exhibited earlier shifts at the phylum level, with increased abundance of *Proteobacteria* and *Cyanobacteria* already detectable on day 6 (Figure 5E). On day 10, a notable enrichment of the *Verrucomicrobiota* phylum was observed. However, the most prominent changes at the genus level were associated with members of the *Firmicutes* and *Bacteroidota*




### 3.4 Different expression in Annexin A1 levels affects the microbiota in IBD patients

CD patients with active inflammation and low AnxA1 expression exhibited distinct microbiota composition compared to healthy controls, mainly presenting an increase in *Lachnospirillum* and *Parabacteroides* genera (Figure 6C). This pattern was not observed in inflamed patients with high AnxA1 levels though (Figure 6A), suggesting that elevated AnxA1 may partially preserve the microbial profile, maintaining it at an intermediate level, still dysbiotic, but less disrupted than in low levels of AnxA1. Moreover, CD patients in the relapse phase with basal or low AnxA1 expression (Figure 6B) showed no significant differences in microbiota composition when compared to healthy controls, but reduced bacterial richness.

UC patients presented the same microbial genera composition regardless of AnxA1 expression level (Figures 6D-F). However, in active disease, the magnitude of AnxA1 expression influenced the phylum, class and order levels of bacteria compared to relapsing





patients. In this scenario, high levels of AnxA1 reflected in an increase at the *Actinobacteriota* and *Bacteroidota* phyla, as an increase in *Parabacteroides*, although the latter has not reached statistical significance (Figure 6D). Likewise, active disease in UC patients with low AnxA1 levels was marked by an increase in *Faecalibacterium* and *Prevotellaceae*, along with a decrease in *Parabacteroides*, although not significantly (Figure 6F). This shift reflects a more dysbiotic and pro-inflammatory microbial profile in the absence of AnxA1. Altogether, these findings suggest impaired anti-inflammatory regulation in AnxA1 deficiency.

If the microbiota of both IBD diseases are compared, it is possible to infer that the disease type may influence bacterial composition in the AnxA1-reduced condition. Non-inflamed CD and UC patients with reduced AnxA1 expression displayed different microbiota profiles (p-value <0.01), with higher abundance of

*Lachnospiraceae* and *Parabacteroides* in CD patients, and lower abundance of *Faecalibacterium* (Figures 6B, E). Bacterial genus richness and evenness were also lower in CD patients. Together, the data obtained here point out that levels of AnxA1, even in the latent or relapsing inflammation, affect the microbiota profile in humans.

## 4 Discussion

The gut microbiota and the immune system are tightly interconnected, and intestinal homeostasis relies on a delicate balance between microbial surveillance, inflammatory responses and their resolution (44). Disruption of this balance, particularly due to deficiencies in pro-resolving mediators, such as AnxA1, impairs the regulation of inflammation and contributes to the




FIGURE 6

Microbiota shifts in IBD with AnxA1 differential expression. Relative abundance of main bacterial genera shifts in the colon of CD and UC subjects compared to control (centered). (A) CD patient with inflamed colon and high AnxA1 expression. (B) CD patient non-inflamed with basal AnxA1 expression. (C) CD patient with inflamed colon and low levels of AnxA1 expression. (D) UC patient with inflamed colon and high AnxA1 expression. (E) UC patient non-inflamed with basal AnxA1 expression. (F) UC patient with inflamed colon and low levels of AnxA1 expression.

pathogenesis of IBDs (33, 37, 41, 45). Although the immunomodulatory roles of AnxA1 on IBD have been described, its influence on microbial dynamics remains poorly understood. In this study, unprecedented data strengthen the evidence for AnxA1's involvement in microbiota modulation, either dependent or independent of the inflammatory state.

Healthy AnxA1-deficient mice presented reduced richness in comparison to WT, which, along with compositional differences in the bacterial community, suggests resilient or functionally limited microbiota with predisposition to exaggerated inflammation upon

stimulation. Among the taxonomic shifts, AnxA1<sup>-/-</sup> mice presented the overgrowth of *Proteobacteria*, which is considered a marker of microbiota instability, leading to immune activation, associated with Toll-like receptor (TLR) expression and inflammatory cytokines release, such as TNF- $\alpha$ , IL-6, and IL-1 $\beta$  (46), rendering the host more susceptible to inflammatory stimuli (18, 47–49). Notwithstanding, a reduction in microbial richness, as observed in AnxA1<sup>-/-</sup> mice, has been correlated with a relative expansion of *Proteobacteria* in IBDs (50). Consistent with this pattern, an increase in *Parasutterella*, which is linked to metabolic and

inflammatory imbalances (51), indicates underlying alterations in epithelial barrier integrity or immune signaling pathways in the absence of AnxA1. In addition, the lower abundance of *Deferribacterota* and *Campylobacterota* in healthy AnxA1<sup>-/-</sup> mice, including their representative genera *Mucispirillum* and *Helicobacter*, which typically colonize mucus-adjacent niches, suggests that AnxA1 influences mucosal microbial colonization under physiological conditions. Notably, *Helicobacter hepaticus*, a species within *Campylobacterota*, has been implicated in shaping Th17 responses, being considered a pathobiont strain by disrupting Treg/Th17 axis in immunodeficient conditions (52).

*Helicobacter* was more abundant in WT and AnxA1<sup>-/-</sup> mice under basal conditions, but its levels markedly increased in the absence of AnxA1 during colitis, erasing the initial differences. This expansion under inflammatory stress may reflect the inability of AnxA1<sup>-/-</sup> mice to effectively restrain immune activation, allowing overgrowth of potentially pro-inflammatory taxa. While *Helicobacter*-driven IL-17A responses (52) may be tightly regulated in WT mice, maintaining mucosal balance, its dysregulation in AnxA1<sup>-/-</sup> animals could amplify inflammation and worsen disease outcomes.

Another genus decreased in AnxA1<sup>-/-</sup> mice was *Prevotellaceae* UCG-001, a bacterium associated with fiber fermentation and SCFA production (53). Its reduction may reflect impaired microbial metabolic function and a shift toward a more pro-inflammatory gut environment (54). The absence of *Alloprevotella* in AnxA1<sup>-/-</sup> mice is also notable, given that this genus is typically associated with the production of SCFAs. Moreover, its presence is often linked to greater microbial diversity, which is generally considered favorable for gut health (55, 56). In contrast, the higher abundance of *Lactobacillus* and *Odoribacter* in AnxA1<sup>-/-</sup> mice may reflect a microbial response associated with the maintenance of intestinal homeostasis. *Odoribacter*, for instance, can modulate macrophage function and epithelial barrier integrity through its metabolites. Loss of *Odoribacter* in colitis is linked to reduced SCFA availability, leading to intestinal inflammation (57, 58). Meanwhile, in dysbiosis, *Lactobacillus* may promote Th1 responses, enhancing the secretion of inflammatory cytokines like IFN- $\gamma$  and TNF- $\alpha$ , contributing to IBD development (59). However, the functional impact of this shift remains unclear, as quantitative changes do not always translate into equivalent functional outcomes. The associated data clearly show a basal difference in microbiota constitution of AnxA1<sup>-/-</sup>, clearly showing that alteration in genotype affected bacteria in the gut. Although the leukocyte population in the gut of healthy AnxA1 or WT are similar, it remains to be evaluated how the absence of AnxA1 affects the microbiota.

As observed in the healthy state, the microbiota of AnxA1<sup>-/-</sup> and WT mice maintained distinct profiles throughout the colitis timeline, suggesting that the lack of AnxA1 actively drives microbiota divergence even under inflammatory conditions. The persistent enrichment of *Proteobacteria* in AnxA1<sup>-/-</sup> mice during the peak of inflammation (day 6) is consistent with prior reports linking this phylum to intestinal dysbiosis, potentially contributing to a more severe inflammatory profile compared to the WT group (60). Furthermore, dysbiosis with a predominance of *Proteobacteria*

may lead to persistent innate immune activation, intensifying neutrophil and macrophage infiltration into the intestinal mucosa and worsening chronic inflammation (61). Interestingly, by day 10, this difference was no longer significant between both genotypes, which may reflect a delayed or altered resolution of the inflammatory response in the absence of AnxA1.

*Firmicutes*, one of the dominant phyla in the healthy gut, were more abundant in AnxA1<sup>-/-</sup> DSS mice at day 10, potentially indicating a compensatory bloom of taxa involved in butyrate production during the recovery phase (62). However, the functional relevance of this expansion remains to be elucidated. The progressive increase in *Verrucomicrobiota* across colitis is aligned with reports of *Akkermansia muciniphila* expansion during epithelial barrier damage or remodeling (63). Also, it was observed that the enrichment of *Akkermansia* through the days in both groups of animals. The disappearance of initial differences by day 10 between the groups may indicate a common mucosal healing process in both genotypes. Importantly, the persistence of *Alloprevotella* exclusively in WT mice across time points reinforces its sensitivity to the AnxA1-dependent mucosal environment. Given the association of this genus with SCFA production and immunoregulatory effects, its absence in AnxA1<sup>-/-</sup> mice may contribute to their distinct inflammatory profile.

Additionally, the increase of *Lachnospiraceae* NK4A136 group and *Bacteroides* in AnxA1<sup>-/-</sup> mice by day 10, overtaking *Muribaculaceae*, may reflect a shift in fermentative capacity or epithelial nutrient availability during recovery (64, 65). *Bacteroides* enrichment during recovery may not signal resolution, but rather a dysbiotic rebound shaped by host-microbiota disequilibrium (66–68). *Parasutterella*, initially enriched in AnxA1<sup>-/-</sup> mice, showed a transient bloom at peak inflammation before returning to WT levels, which may indicate a context-dependent interaction with host immunity or metabolic state. These bacteria produce succinate, which aids microbiota recovery but also promotes ulceration in DSS-colitis (69). In IBDs, excessive succinate drives inflammation by activating immune cells, HIF-1 $\alpha$ , and IL-1 $\beta$ , while also fueling pathogens like *C. difficile*, disrupting microbial balance (70–72).

The dynamics of gut microbiota during experimental colitis reveal a distinct temporal pattern between WT and AnxA1<sup>-/-</sup> mice, suggesting that AnxA1 plays a critical role in modulating the microbial response to inflammation. In WT mice, meaningful microbiota changes only emerged later during disease progression in comparison to AnxA1<sup>-/-</sup>, whereas AnxA1<sup>-/-</sup> mice exhibited earlier shifts. These findings suggest that the absence of AnxA1 predisposes the gut environment to dysbiosis more rapidly during inflammatory stress, in line with its known regulatory functions in mucosal immunity and tissue homeostasis (73).

Although both WT and AnxA1<sup>-/-</sup> mice developed colitis, the heightened severity of the model may have obscured subtle differences between strains. Nevertheless, AnxA1<sup>-/-</sup> mice showed greater weight loss and increased circulating neutrophils, suggesting a more intense and unresolved inflammatory response. This is consistent with the known role of AnxA1 in regulating neutrophil physiology, including their release from the bone marrow, migration to inflamed tissues, apoptosis, and clearance by M2

macrophages in homing tissues (24, 74–76). In its absence, these processes become dysregulated, leading to persistent neutrophilia and impaired resolution. Additionally, the observed lymphopenia likely reflects lymphocyte recruitment to the inflamed colon, a process also influenced by AnxA1 through its modulation of leukocyte trafficking (34, 76, 77).

While AnxA1 also governs monocyte infiltration and promotes anti-inflammatory M2 macrophage polarization, no increase in macrophage numbers was detected by day 10 of colitis. This may be due to a predominance of pro-inflammatory M1 macrophages in AnxA1<sup>-/-</sup> mice or limitations in detection, as F4/80 alone may not adequately distinguish between macrophage subtypes, highlighting the need for more specific markers in future analyses (26, 78–80).

Together, these data indicate that AnxA1 plays a key role in modulating gut microbiota dynamics during experimental colitis. While overall alpha diversity remained stable, AnxA1<sup>-/-</sup> mice exhibited earlier and more pronounced taxonomic shifts compared to WT, suggesting increased susceptibility to inflammation-associated dysbiosis. These changes, particularly involving reductions in SCFA-producing bacteria and expansions of *Proteobacteria*, likely reflect impaired regulation of immune-microbiota interactions in the absence of AnxA1. The findings indicate that AnxA1 contributes to gut homeostasis by fine-tuning microbial composition over time and orchestrating a more balanced response and recovery to inflammatory stress, highlighting its relevance in mucosal immunity and the resolution of inflammation.

To determine whether these findings translate to human disease, we further investigated the relationship between AnxA1 expression and microbiota composition in patients with IBD. Studies have shown that alpha-diversity in IBDs, particularly in CD, is typically reduced compared to healthy individuals, with lower species richness and uneven microbial distribution, often marked by a loss of beneficial bacteria. This decrease is associated with more severe symptoms and chronic inflammation (81). In this study, non-inflamed CD patients with low AnxA1 expression had reduced species richness compared to controls. Such differences were not seen in patients with higher AnxA1, regardless of inflammation. These findings suggest that AnxA1 may be associated with maintaining the balance of alpha-diversity in IBD, sustaining homeostasis and preventing the worsening of inflammation.

Although UC patients showed no difference in richness compared to controls, the evenness of bacteria in UC-inflamed subjects with high AnxA1 was decreased compared to controls. Thus, while bacterial distribution varied in this group, the genera and total number of bacteria still resembled those of a healthy control, suggesting that AnxA1, particularly its high expression, may contribute to maintaining eubiosis. Non-inflamed CD subjects with low expression of AnxA1 also presented less richness and evenness when compared to UC ones. This change may highlight how disease basal dynamics and location are also influenced by overall microbial composition and its interactions with the immune resolutive system.

In the present study, differences in the microbiota of inflamed patients with low AnxA1 expression in CD were found compared to

controls, but not in individuals with high AnxA1 expression. No differences were found between inflamed individuals with high AnxA1 expression and controls. This shows that while healthy individuals and those inflamed with low AnxA1 expression have distinct microbiotas, individuals with high levels of AnxA1 display an intermediate profile between the two of them.

Moreover, UC patients with active inflammation but with low AnxA1 expression exhibited different microbial composition than their counterparts with higher AnxA1 levels. These differences were observed primarily at the phylum, class, and order levels, suggesting subtle but specific shifts in community structure even in the absence of overt inflammation. However, no significant differences were found between these UC subgroups and healthy controls, indicating that changes associated with reduced AnxA1 in UC may not yet reach the level of dysbiosis detectable against a healthy baseline. In contrast, CD patients without inflammation but with low AnxA1 expression showed a markedly different microbiota composition compared to UC subjects with similarly low AnxA1 expression. The most notable alterations also included an increase in *Lachnoclostridium* and *Parabacteroides* in CD, alongside a reduction in *Faecalibacterium*. These findings suggest that the impact of AnxA1 deficiency on microbiota composition may be disease-specific and more pronounced in the context of CD. Altogether, these results highlight a potential role for AnxA1 in shaping gut microbial ecology even in the absence of inflammation and raise the possibility that low AnxA1 expression may prime the intestinal environment for disease progression in a disease-dependent manner.

*Faecalibacterium* is a key butyrate-producing genus involved in maintaining intestinal homeostasis by promoting anti-inflammatory macrophage polarization (M2), inducing Treg differentiation, and stimulating IL-10 production (82). Its reduction in IBD has been associated with increased inflammation, impaired epithelial barrier function, and heightened innate immune activation (83, 84). Despite its known relevance, this study did not reveal a clear difference in *Faecalibacterium* abundance across stratified patient groups.

*Parabacteroides* is considered a context-dependent genus within the gut microbiota. Its role in the gut is not universally good or bad, but shaped by host-microbe interactions, microbial context, and immune status. In murine models, *Parabacteroides distasonis* has been shown to stimulate IL-10 production and attenuate experimental colitis (85, 86). Furthermore, a synergistic effect between *P. distasonis* and *Akkermansia muciniphila* has been reported to protect against both acute and chronic colitis by enhancing epithelial barrier integrity and promoting the accumulation of group 3 innate lymphoid cells (ILC3s) in the colonic mucosa (87). In CD, however, its colonization has been associated with depressive-like behaviors, possibly due to gut-brain axis interactions (88). The abundance of *Parabacteroides* is influenced by various factors, with some species displaying notable resilience to antimicrobial treatments (89, 90). In this study, inflamed CD patients with low AnxA1 expression exhibited approximately twice the abundance of *Parabacteroides* compared to controls and those with high AnxA1 levels, a pattern



not observed in UC. In *AnxA1*<sup>-/-</sup> mice, *Parabacteroides* levels increased throughout experimental colitis, with *Parabacteroides goldsteinii* being the only species identified. By day 10 of colitis, *P. goldsteinii* abundance was higher in *AnxA1*<sup>-/-</sup> mice compared to WT. Overall, the genus remained more abundant in WT animals, suggesting complex and context-dependent regulatory dynamics mediated by *AnxA1*.

A key limitation of our study is that, although *AnxA1* deficiency was associated with distinct microbial shifts and worsened colitis outcomes, our data do not allow us to determine whether these alterations in the microbiota act as causal drivers of pathology or merely represent secondary consequences of inflammation. Establishing this directionality would require dedicated mechanistic approaches, such as fecal microbiota transfer (FMT), to directly test whether the observed microbial profiles can modulate disease severity in the context of *AnxA1* signaling. In this regard, our discussion of potential metabolic consequences was grounded in previously published functional studies of the bacterial taxa identified, providing a conceptual framework and rationale for future investigations to address this cause–consequence interplay.

Other resolvins, especially the ones derived from eicosapentaenoic acid-EPA RvE1 and RvE2, and from the docosahexaenoic acid-DHA RvD1, AT-RvD1 and RvD2, have emerged as pivotal regulators of intestinal inflammation (91). In experimental colitis models, they mitigate classical features of disease activity, including weight loss, colon shortening, neutrophil infiltration, and cytokine production, while simultaneously enhancing macrophage phagocytosis and epithelial barrier protection (92–94). Mechanistically, these resolvins signal through specific receptors, such as Leukotriene B4 receptor 1 (BLT1), Lipoxin A4 receptor (ALX)/FPR2, and Chemokine-like receptor 1 (CMKLR1), thereby dampening nuclear factor kappa B (NF-κB) activation, reducing adhesion molecule expression, and facilitating the non-inflammatory clearance of apoptotic cells (93, 95, 96).

In the clinical context, differential expression of resolvins has been linked to disease activity in both CD and UC. Notably, RvE1 levels were consistently lower in CD than in UC, and in the active phase, this lipid mediator emerged as a potential discriminator between the two entities. In UC patients, remission was also more strongly associated with RvE1 and correlated with lower clinical and endoscopic activity, suggesting its potential utility as a biomarker of mucosal healing (97, 98). Importantly, RvD2 also attenuates DSS-induced colitis, demonstrating efficacy comparable to anti-TNF therapy in preclinical settings, underscoring its translational potential (99).

Campbell et al. (100) demonstrated that RvE1 protects against DSS-induced colitis, likely through the activation of intestinal alkaline phosphatase, which helps detoxify bacterial lipopolysaccharides. Similarly, Zeng et al. (101) showed that RvD1 ameliorates hepatic steatosis in DSS-induced chronic colitis by reshaping the gut microbiota. RvD1 treatment restored a healthier microbial profile resembling that of control mice, normalized the *Firmicutes*-to-*Bacteroidetes* ratio, increased beneficial bacteria such as *Akkermansia*, and reduced genera like *Bacteroides* and *Desulfovibrio*. These microbiota changes were associated with improved intestinal barrier integrity and reduced systemic inflammation, suggesting that RvD1 exerts its protective effects through modulation of the gut–liver axis.

Taken together, these observations highlight resolvins as not only candidate therapeutic targets but also as biomarkers capable of distinguishing disease phases and entities. Functionally, they appear to mirror several actions attributed to Annexin A1, supporting the notion that convergent pro-resolving pathways act in parallel to restrain intestinal inflammation and promote mucosal homeostasis.

In this context, studies investigating *AnxA1* in the setting of IBD treatment have been increasingly reported. *AnxA1*-mimetic peptides, such as Ac2-26, reproduce many of the anti-inflammatory and pro-resolving actions of the native protein, including inhibition of neutrophil infiltration, promotion of macrophage-mediated clearance, and restoration of epithelial barrier integrity (38). Polymeric nanoparticles loaded with Ac2-26 have been tested in murine models of colitis, where they accelerated epithelial wound healing and promoted intestinal tissue regeneration (40). Li et al. (102) further demonstrated that Ac2-26-containing nanoparticles reshaped the microbiota of DSS-induced mice, reducing the expansion of *Escherichia-Shigella* and increasing levels of *Prevotellaceae*. Alpha and beta diversity did not differ from control groups after nanotherapy treatment. Taken together with our findings, and supported by previous evidence showing that *AnxA1* deficiency alters gut microbial composition and exacerbates colitis, these peptides may represent a dual-action therapeutic strategy: directly resolving inflammation while indirectly modulating the gut microbiota. Future studies are warranted to determine whether *AnxA1*-mimetic peptides can favorably reshape microbial communities and translate these mechanistic insights into therapeutic benefit for patients with IBD.

Altogether, the results presented here suggest that *AnxA1* plays a key role in shaping the intestinal microbiota through its immunomodulatory effects, both in experimental colitis and in IBD patients. In murine models, the absence of *AnxA1* led to early and more pronounced dysbiotic shifts during colitis. Even under healthy conditions, *AnxA1*<sup>-/-</sup> mice exhibited reduced microbial richness and distinct community structures, indicating that *AnxA1* contributes to maintaining microbiota resilience and mucosal homeostasis. In human cohorts, patients with higher *AnxA1* expression, regardless of inflammatory status, had microbial profiles more similar to healthy controls, with greater uniformity and richness, suggesting that *AnxA1* may protect against microbiota disruption and excessive inflammation. Differences in microbial composition among IBD subtypes further suggest that the influence of *AnxA1* on the gut ecosystem may be disease-specific and dependent on the inflammatory context. Hence, these findings underscore the critical role of *AnxA1* in orchestrating host–microbiota interactions and maintaining intestinal equilibrium. They also highlight the therapeutic potential of targeting *AnxA1* pathways to restore microbiota balance and reduce inflammation in IBD.

## Data availability statement

The datasets analyzed for this study can be found in the European Genome-Phenome Archive <https://ega-archive.org/studies/EGAS00001005027>.

## Ethics statement

The studies involving humans were approved by Ethics committee of the University of Groningen. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements. The animal study was approved by Ethics Committee of Animal Use of the Faculty of Pharmaceutical Sciences of the University of São Paulo-CEUA/FCF/USP. The study was conducted in accordance with the local legislation and institutional requirements.

## Author contributions

LF: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. RG: Conceptualization, Investigation, Methodology, Writing – review & editing. Gd: Investigation, Methodology, Writing – review & editing. MB: Investigation, Methodology, Writing – review & editing. PS: Investigation, Methodology, Writing – review & editing. FL: Investigation, Methodology, Writing – review & editing. KF: Methodology, Project administration, Resources, Supervision, Writing – review & editing. HH: Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing. CH: Methodology, Project administration, Resources, Supervision, Writing – review & editing. SF: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing.

## Funding

The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), PrInt-CAPES (Programa Institucional de Internacionalização da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), grant number 2022/11602-0/2024/15297-3. PS is a FAPESP fellowship (grant number 2020/14368-3).

## References

1. Dolinger M, Torres J, Vermeire S. Crohn's disease. *Lancet*. (2024) 403:1177–91. doi: 10.1016/S0140-6736(23)02586-2
2. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E, et al. ECCO guidelines on inflammatory bowel disease and Malignancies. *J Crohns Colitis*. (2023) 17:827–54. doi: 10.1093/ecco-jcc/jjac187
3. Gros B, Kaplan GG. Ulcerative colitis in adults: A review. *JAMA*. (2023) 330:951–65. doi: 10.1001/jama.2023.15389
4. Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. *J Gastroenterol*. (2021) 56:489–526. doi: 10.1007/s00535-021-01784-1

## Acknowledgments

We thank Dr. Sandra Farsky, Dr. Christian Hoffmann, Dr. Hermie Harmsen, and Dr. Klaas Nico Faber for their financial support and valuable scientific input in the conception of this work. We also acknowledge the collaborative efforts between the University of São Paulo and the University of Groningen, which were essential for the development of this study. Finally, we thank our colleagues for their contributions and constructive discussions throughout the project.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2025.1679071/full#supplementary-material>

5. Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. *Gastroenterology*. (2022) 162:715–30.e3. doi: 10.1053/j.gastro.2021.10.035
6. Zhernakova DV, Wang D, Liu L, Andreu-Sánchez S, Zhang Y, Ruiz-Moreno AJ, et al. Host genetic regulation of human gut microbial structural variation. *Nature*. (2024) 625:813–21. doi: 10.1038/s41586-023-06893-w
7. Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, et al. Gut microbiota is a potential biomarker in inflammatory bowel disease. *Front Nutr*. (2022) 8:818902. doi: 10.3389/fnut.2021.818902
8. Mestrovic A, Perkovic N, Bozic D, Kumric M, Vilovic M, Bozic J. Precision medicine in inflammatory bowel disease: A spotlight on emerging molecular biomarkers. *Biomedicines*. (2024) 12:1520. doi: 10.3390/biomedicines12071520
9. Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, et al. Understanding the therapeutic toolkit for inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol*. (2025) 22:371–94. doi: 10.1038/s41575-024-01035-7
10. Al Radi ZMA, Prins FM, Colliv V, Vich Vila A, Festen EAM, Dijkstra G, et al. Exploring the predictive value of gut microbiome signatures for therapy intensification in patients with inflammatory bowel disease: A 10-year follow-up study. *Inflammation Bowel Dis*. (2024) 30:1642–53. doi: 10.1093/ibd/izae064
11. Chen L, Zhang C, Niu R, Xiong S, He J, Wang Y, et al. Multi-omics biomarkers for predicting efficacy of biologic and small-molecule therapies in adults with inflammatory bowel disease: A systematic review. *United Eur Gastroenterol J*. (2025) 13:517–30. doi: 10.1002/ueg2.12720
12. Hu S, Bourgonje AR, Gacesa R, Jansen BH, Björk JR, Bangma A, et al. Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease. *Nat Commun*. (2024) 15:1470. doi: 10.1038/s41467-024-45855-2
13. Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sasaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. *World J Gastroenterol*. (2022) 28:4053–60. doi: 10.3748/wjg.v28.i30.4053
14. Haneishi Y, Furuya Y, Hasegawa M, Picarelli A, Rossi M, Miyamoto J. Inflammatory bowel diseases and gut microbiota. *Int J Mol Sci*. (2023) 24:3817. doi: 10.3390/ijms24043817
15. Iliev ID, Ananthakrishnan AN, Guo C-J. Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. *Nat Rev Microbiol*. (2025) 23:509–24. doi: 10.1038/s41579-025-01163-0
16. Pandey H, Jain D, Tang DWT, Wong SH, Lal D. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. *Intest Res*. (2024) 22:15–43. doi: 10.5217/ir.2023.00080
17. Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The gut microbiota in inflammatory bowel disease. *Front Cell Infect Microbiol*. (2022) 12:733992. doi: 10.3389/fcimb.2022.733992
18. Shin Y, Han S, Kwon J, Ju S, Choi TG, Kang I, et al. Roles of short-chain fatty acids in inflammatory bowel disease. *Nutrients*. (2023) 15:4466. doi: 10.3390/nu15204466
19. Yi C, Huang S, Zhang W, Guo L, Xia T, Huang F, et al. Synergistic interactions between gut microbiota and short chain fatty acids: Pioneering therapeutic frontiers in chronic disease management. *Microb Pathog*. (2025) 199:107231. doi: 10.1016/j.micpath.2024.107231
20. Araújo TG, Mota STS, Ferreira HSV, Ribeiro MA, Goulart LR, Vecchi L. Annexin A1 as a regulator of immune response in cancer. *Cells*. (2021) 10:2245. doi: 10.3390/cells10092245
21. Leoni G, Nusrat A. Annexin A1: shifting the balance towards resolution and repair. *Biol Chem*. (2016) 397:971–9. doi: 10.1515/hsz-2016-0180
22. Sandri S, Hebeda CB, Broering MF, de Paula Silva M, Moredo LF, de Barros e Silva MJ, et al. Role of annexin A1 secreted by neutrophils in melanoma metastasis. *Cells*. (2023) 12:425. doi: 10.3390/cells12030425
23. Perez GI, Bernard MP, Vocelle D, Zarea AA, Saleh NA, Gagea MA, et al. Phosphatidylserine-exposing Annexin A1-positive extracellular vesicles: potential cancer biomarkers. *Vaccines (Basel)*. (2023) 11:639. doi: 10.3390/vaccines11030639
24. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. *Nat Rev Immunol*. (2009) 9:62–70. doi: 10.1038/nri2470
25. Moreli JB, Santos MRD, Calderon I, de MP, Hebeda CB, Farsky SHP, et al. The role of Annexin A1 in DNA damage response in placental cells: impact on gestational diabetes mellitus. *Int J Mol Sci*. (2023) 24:10155. doi: 10.3390/ijms241210155
26. Sheikh MH, Solito E. Annexin A1: uncovering the many talents of an old protein. *Int J Mol Sci*. (2018) 19:1045. doi: 10.3390/ijms19041045
27. Sousa SO, Santos MRD, Teixeira SC, Ferro EAV, Oliani SM. ANNEXIN A1: roles in placenta, cell survival, and nucleus. *Cells*. (2022) 11:2057. doi: 10.3390/cells11132057
28. Xia Q, Li X, Zhou H, Zheng L, Shi J. S100A11 protects against neuronal cell apoptosis induced by cerebral ischemia via inhibiting the nuclear translocation of annexin A1. *Cell Death Dis*. (2018) 9:657. doi: 10.1038/s41419-018-0686-7
29. D'Acquisto F, Perretti M, Flower RJ. Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. *Br J Pharmacol*. (2008) 155:152–69. doi: 10.1038/bjp.2008.252
30. Qin CX, Norling LV, Vecchio EA, Brennan EP, May LT, Wootten D, et al. Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35. *Br J Pharmacol*. (2022) 179:4617–39. doi: 10.1111/bph.15919
31. Grewal T, Wason SJ, Enrich C, Rentero C. Annexins - insights from knockout mice. *Biol Chem*. (2016) 397:1031–53. doi: 10.1515/hsz-2016-0168
32. Zharkova O, Salamah MF, Babak MV, Rajan E, Lim LHK, Andrade F, et al. Deletion of annexin A1 in mice upregulates the expression of its receptor, fpr2/3, and reactivity to the anxA1 mimetic peptide in platelets. *Int J Mol Sci*. (2023) 24:3424. doi: 10.3390/ijms24043424
33. de Paula-Silva M, Barrios BE, Macciò-Maretto L, Sena AA, Farsky SHP, Correa SG, et al. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis. *Biochem Pharmacol*. (2016) 115:104–13. doi: 10.1016/j.bcp.2016.06.012
34. Leoni G, Alam A, Neumann P-A, Lambeth JD, Cheng G, McCoy J, et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. *J Clin Invest*. (2013) 123:443–54. doi: 10.1172/JCI65831
35. Vergnolle N, Pagès P, Guimbaud R, Chaussade S, Buéno L, Escourrou J, et al. Annexin I is secreted *in situ* during ulcerative colitis in humans. *Inflammation Bowel Dis*. (2004) 10:584–92. doi: 10.1097/00054725-200409000-00013
36. da Rocha GHO, de Paula-Silva M, Broering MF, Scharf PRDS, Matsuyama LSAS, Maria-Engler SS, et al. Pioglitazone-mediated attenuation of experimental colitis relies on cleaving of Annexin A1 released by macrophages. *Front Pharmacol*. (2020) 11:591561. doi: 10.3389/fphar.2020.591561
37. de Paula-Silva M, da Rocha GHO, Broering MF, Queiroz ML, Sandri S, Loiola RA, et al. Formyl peptide receptors and Annexin A1: complementary mechanisms to infliximab in murine experimental colitis and Crohn's disease. *Front Immunol*. (2021) 12:714138. doi: 10.3389/fimmu.2021.714138
38. Broering MF, Oseliero Filho PL, Borges PP, da Silva LCC, Knirsch MC, Xavier LF, et al. Development of Ac2-26 mesoporous microparticle system as a potential therapeutic agent for inflammatory bowel diseases. *Int J Nanomedicine*. (2024) 19:3537–54. doi: 10.2147/IJN.S451589
39. Broering MF, Leão M, de C, da Rocha GHO, Scharf P, Xavier LF, et al. Development of Annexin A1-surface-functionalized metal-complex multi-wall lipid core nanocapsules and effectiveness on experimental colitis. *Eur J Pharm Biopharm*. (2022) 181:49–59. doi: 10.1016/j.ejpb.2022.10.022
40. Leoni G, Neumann P-A, Kamaly N, Quiros M, Nishio H, Jones HR, et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. *J Clin Invest*. (2015) 125:1215–27. doi: 10.1172/JCI76693
41. Xu R, Weber M-C, Hu X, Neumann P-A, Kamaly N. Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy. *Semin Immunol*. (2022) 61–64:101664. doi: 10.1016/j.smim.2022.101664
42. Valle-Noguera A, Gómez-Sánchez MJ, Girard-Madoux MJH, Cruz-Adalia A. Optimized protocol for characterization of mouse gut innate lymphoid cells. *Front Immunol*. (2020) 11:563414. doi: 10.3389/fimmu.2020.563414
43. Caporaso JG, Lauber CL, Walters WA, Lozupone CA, Turnbaugh PJ, Fierer N, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc Natl Acad Sci*. (2011) 108:4516–22. doi: 10.1073/pnas.1000080107
44. Wang J, He M, Yang M, Ai X. Gut microbiota as a key regulator of intestinal mucosal immunity. *Life Sci*. (2024) 345:122612. doi: 10.1016/j.lfs.2024.122612
45. Sena A, Grishina I, Thai A, Goulart L, Macal M, Fenton A, et al. Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease. *PLoS One*. (2013) 8:e76969. doi: 10.1371/journal.pone.0076969
46. Peña-Durán E, García-Galindo JJ, López-Murillo LD, Huerta-Huerta A, Balleza-Alejandri LR, Beltrán-Ramírez A, et al. Microbiota and inflammatory markers: A review of their interplay, clinical implications, and metabolic disorders. *Int J Mol Sci*. (2025) 26:1773. doi: 10.3390/ijms26041773
47. Mukhopadhyay I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? *Nat Rev Gastroenterol Hepatol*. (2012) 9:219–30. doi: 10.1038/nrgastro.2012.14
48. Ooi JH, Waddell A, Lin Y-D, Albert I, Rust LT, Holden V, et al. Dominant effects of the diet on the microbiome and the local and systemic immune response in mice. *PLoS One*. (2014) 9:e86366. doi: 10.1371/journal.pone.0086366
49. Yee S-M, Choi H, Seon J-E, Ban Y-J, Kim M-J, Seo J-E, et al. Axl alleviates DSS-induced colitis by preventing dysbiosis of gut microbiota. *Sci Rep*. (2023) 13:5371. doi: 10.1038/s41598-023-32527-2
50. Zheng J, Sun Q, Zhang M, Liu C, Su Q, Zhang L, et al. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. *Nat Med*. (2024) 30:3555–67. doi: 10.1038/s41591-024-03280-4
51. Ju T, Kong JY, Stothard P, Willing BP. Defining the role of Parasutterella, a previously uncharacterized member of the core gut microbiota. *ISME J*. (2019) 13:1520–34. doi: 10.1038/s41396-019-0364-5
52. Morrison PJ, Bending D, Fouser LA, Wright JF, Stockinger B, Cooke A, et al. Th17-cell plasticity in Helicobacter hepaticus-induced intestinal inflammation. *Mucosal Immunol*. (2013) 6:1143–56. doi: 10.1038/mi.2013.11
53. Song X, Zhong L, Lyu N, Liu F, Li B, Hao Y, et al. Inulin can alleviate metabolism disorders in ob/ob mice by partially restoring leptin-related pathways mediated by gut microbiota. *Genomics Proteomics Bioinf*. (2019) 17:64–75. doi: 10.1016/j.gpb.2019.03.001



54. Hong C-T, Chan L, Chen K-Y, Lee H-H, Huang L-K, Yang Y.-C.S.H., et al. Rifaximin modifies gut microbiota and attenuates inflammation in Parkinson's disease: preclinical and clinical studies. *Cells*. (2022) 11:3468. doi: 10.3390/cells11213468
55. Han B, Shi L, Bao M-Y, Yu F-L, Zhang Y, Lu X-Y, et al. Dietary ellagic acid therapy for CNS autoimmunity: Targeting on *Alloprevotella rava* and propionate metabolism. *Microbiome*. (2024) 12:114. doi: 10.1186/s40168-024-01819-8
56. Pietrucci D, Teofani A, Milanesi M, Fosso B, Putignani L, Messina F, et al. Machine learning data analysis highlights the role of *Parasutterella* and *Alloprevotella* in autism spectrum disorders. *Biomedicines*. (2022) 10:2028. doi: 10.3390/biomedicines10082028
57. Dai J, Jiang M, Wang X, Lang T, Wan L, Wang J. Human-derived bacterial strains mitigate colitis via modulating gut microbiota and repairing intestinal barrier function in mice. *BMC Microbiol*. (2024) 24:96. doi: 10.1186/s12866-024-03216-5
58. Zhuang J, Zhuang Z, Chen B, Yang Y, Chen H, Guan G. *Odoribacter splanchnicus*-derived extracellular vesicles alleviate inflammatory bowel disease by modulating gastrointestinal inflammation and intestinal barrier function via the NLRP3 inflammasome suppression. *Mol Med*. (2025) 31:56. doi: 10.1186/s10020-025-01063-2
59. Guo N, Lv L-L. Mechanistic insights into the role of probiotics in modulating immune cells in ulcerative colitis. *Immun Inflammation Dis*. (2023) 11:e1045. doi: 10.1002/iid3.1045
60. Ma J, Wang K, Wang J, Zeng Q, Liu K, Zheng S, et al. Microbial disruptions in inflammatory bowel disease: A comparative analysis. *Int J Gen Med*. (2024) 17:1355–67. doi: 10.2147/IJGM.S448359
61. Molloy MJ, Grainger JR, Bouladoux N, Hand TW, Koo LY, Naik S, et al. Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis. *Cell Host Microbe*. (2013) 14:318–28. doi: 10.1016/j.chom.2013.08.003
62. Esquerre N, Basso L, Defaye M, Vicentini FA, Cluny N, Bihan D, et al. Colitis-induced microbial perturbation promotes postinflammatory visceral hypersensitivity. *Cell Mol Gastroenterol Hepatol*. (2020) 10:225–44. doi: 10.1016/j.jcmgh.2020.04.003
63. Qu S, Zheng Y, Huang Y, Feng Y, Xu K, Zhang W, et al. Excessive consumption of mucin by over-colonized *Akkermansia muciniphila* promotes intestinal barrier damage during Malignant intestinal environment. *Front Microbiol*. (2023) 14:1111911. doi: 10.3389/fmicb.2023.1111911
64. Dou X, Gao N, Yan D, Shan A. Sodium butyrate alleviates mouse colitis by regulating gut microbiota dysbiosis. *Anim (Basel)*. (2020) 10:1154. doi: 10.3390/ani10071154
65. Schwab C, Berry D, Rauch I, Rennisch I, Ramesmayer J, Hainzl E, et al. Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. *ISME J*. (2014) 8:1101–14. doi: 10.1038/ismej.2013.223
66. Bloom SM, Bijanki VN, Nava GM, Sun L, Malvin NP, Donermeyer DL, et al. Commensal *Bacteroides* species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. *Cell Host Microbe*. (2011) 9:390–403. doi: 10.1016/j.chom.2011.04.009
67. Bourgonje AR, Roo-Brand G, Lisotto P, Sadaghian Sadabad M, Reitsema RD, de Goffau MC, et al. Patients with inflammatory bowel disease show IgG immune responses towards specific intestinal bacterial genera. *Front Immunol*. (2022) 13:842911. doi: 10.3389/fimmu.2022.842911
68. Li F, Yu C, Zhao Q, Wang Z, Wang Z, Chang Y, et al. Exploring the intestinal ecosystem: from gut microbiota to associations with subtypes of inflammatory bowel disease. *Front Cell Infect Microbiol*. (2023) 13:1304858. doi: 10.3389/fcimb.2023.1304858
69. Osaka T, Moriyama E, Arai S, Date Y, Yagi J, Kikuchi J, et al. Meta-analysis of fecal microbiota and metabolites in experimental colitic mice during the inflammatory and healing phases. *Nutrients*. (2017) 9:1329. doi: 10.3390/nu9121329
70. Auria E, Deschamps J, Briandet R, Dupuy B. Extracellular succinate induces spatially organized biofilm formation in *Clostridioides difficile*. *Biofilm*. (2023) 5:100125. doi: 10.1016/j.biofilm.2023.100125
71. Fernández-Veledo S, Grau-Bové C, Notararigo S, Huber-Ruano I. The role of microbial succinate in the pathophysiology of inflammatory bowel disease: mechanisms and therapeutic potential. *Curr Opin Microbiol*. (2025) 85:102599. doi: 10.1016/j.mib.2025.102599
72. Huang H, Li G, He Y, Chen J, Yan J, Zhang Q, et al. Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention. *Front Immunol*. (2024) 15:1404441. doi: 10.3389/fimmu.2024.1404441
73. Gobetti T, Cooray SN. Annexin A1 and resolution of inflammation: tissue repairing properties and signalling signature. *Biol Chem*. (2016) 397:981–93. doi: 10.1515/hsz-2016-0200
74. Dalli J, Jones CP, Cavalcanti DM, Farsky SH, Perretti M, Rankin SM. Annexin A1 regulates neutrophil clearance by macrophages in the mouse bone marrow. *FASEB J*. (2012) 26:387–96. doi: 10.1096/fj.11-182089
75. MaChado ID, Spatti M, Hastreiter A, Santin JR, Fock RA, Gil CD, et al. Annexin A1 is a physiological modulator of neutrophil maturation and recirculation acting on the CXCR4/CXCL12 pathway. *J Cell Physiol*. (2016) 231:2418–27. doi: 10.1002/jcp.25346
76. Sugimoto MA, Vago JP, Teixeira MM, Sousa LP. Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance. *J Immunol Res*. (2016) 2016:8239258. doi: 10.1155/2016/8239258
77. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca<sup>2+</sup> signalling to membrane dynamics. *Nat Rev Mol Cell Biol*. (2005) 6:449–61. doi: 10.1038/nrm1661
78. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. *Funct Differentiation*. *Front Immunol*. (2014) 5:514. doi: 10.3389/fimmu.2014.00514
79. Lima KM, Vago JP, Caux TR, Negreiros-Lima GL, Sugimoto MA, Tavares LP, et al. The resolution of acute inflammation induced by cyclic AMP is dependent on annexin A1. *J Biol Chem*. (2017) 292:13758–73. doi: 10.1074/jbc.M117.800391
80. Yona S, Heinsbroek SEM, Peiser L, Gordon S, Perretti M, Flower RJ. Impaired phagocytic mechanism in annexin 1 null macrophages. *Br J Pharmacol*. (2006) 148:469–77. doi: 10.1038/sj.bjp.0706730
81. Buffet-Bataillon S, Durão G, Le Huërou-Luron I, Rué O, Le Cunff Y, Cattoir V, et al. Gut microbiota dysfunction in Crohn's disease. *Front Cell Infect Microbiol*. (2025) 15:1540352. doi: 10.3389/fcimb.2025.1540352
82. Qiu X, Zhang M, Yang X, Hong N, Yu C. *Faecalibacterium prausnitzii* upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. *J Crohns Colitis*. (2013) 7:e558–568. doi: 10.1016/j.jcrohns.2013.04.002
83. Cao Y, Shen J, Ran ZH. Association between *Faecalibacterium prausnitzii* reduction and inflammatory bowel disease: A meta-analysis and systematic review of the literature. *Gastroenterol Res Pract*. (2014) 2014:872725. doi: 10.1155/2014/872725
84. Fagundes RR, Bravo-Ruiseco G, Hu S, Kierans SJ, Weersma RK, Taylor CT, et al. *Faecalibacterium prausnitzii* promotes intestinal epithelial IL-18 production through activation of the HIF1 $\alpha$  pathway. *Front Microbiol*. (2023) 14:1298304. doi: 10.3389/fmicb.2023.1298304
85. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *Proc Natl Acad Sci U S A*. (2017) 114:10713–8. doi: 10.1073/pnas.1711235114
86. Cui Y, Zhang L, Wang X, Yi Y, Shan Y, Liu B, et al. Roles of intestinal *Parabacteroides* in human health and diseases. *FEMS Microbiol Lett*. (2022) 369:fnac072. doi: 10.1093/femsle/fnac072
87. Gaifem J, Mendes-Frias A, Wolter M, Steimle A, Garzón MJ, Ubeda C, et al. *Akkermansia muciniphila* and *Parabacteroides distasonis* synergistically protect from colitis by promoting ILC3 in the gut. *mBio*. (2024) 15:e0007824. doi: 10.1128/mbio.00078-24
88. Gomez-Nguyen A, Basson AR, Dark-Fleury L, Hsu K, Osme A, Menghini P, et al. *Parabacteroides distasonis* induces depressive-like behavior in a mouse model of Crohn's disease. *Brain Behav Immun*. (2021) 98:245–50. doi: 10.1016/j.bbi.2021.08.218
89. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of *Bacteroides fragilis* group in Canada in 2010–2011: CANWARD surveillance study. *Antimicrob Agents Chemother*. (2012) 56:1247–52. doi: 10.1128/AAC.05823-11
90. Snyderman DR, Jacobus NV, McDermott LA, Goldstein EJC, Harrell L, Jenkins SG, et al. Trends in antimicrobial resistance among *Bacteroides* species and *Parabacteroides* species in the United States from 2010–2012 with comparison to 2008–2009. *Anaerobe*. (2017) 43:21–6. doi: 10.1016/j.anaerobe.2016.11.003
91. Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. *Eur J Pharmacol*. (2016) 785:156–64. doi: 10.1016/j.ejphar.2015.08.050
92. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. *Proc Natl Acad Sci U S A*. (2005) 102:7671–6. doi: 10.1073/pnas.0409271102
93. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators (17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. *J Immunol*. (2011) 187:1957–69. doi: 10.4049/jimmunol.1101305
94. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, et al. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. *Inflammation Bowel Dis*. (2010) 16:87–95. doi: 10.1002/ibd.21029
95. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med*. (2005) 201:713–22. doi: 10.1084/jem.20042031
96. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. *Nature*. (2007) 447:869–74. doi: 10.1038/nature05877
97. Kikut J, Drozd A, Mokrzycka M, Grzybowska-Chlebowczyk U, Ziętek M, Szczuko M. Are EPA and DHA derivatives involved in IBD remission? *J Clin Med*. (2022) 11:2388. doi: 10.3390/jcm11092388
98. Küçük İ, Tural E, Güney B.Ç., Salmanoğlu M, Kaplan M. Evaluation of serum resolvin d1 and e1 levels in patients with inflammatory bowel diseases. *Eskisehir Med J*. (2023) 4:212–9. doi: 10.48176/esmj.2023.135
99. Chaim FHM, Pascoal LB, de Castro MM, Palma BB, Rodrigues BL, Fagundes JJ, et al. The resolvin D2 and omega-3 polyunsaturated fatty acid as a new possible therapeutic approach for inflammatory bowel diseases. *Sci Rep*. (2024) 14:28698. doi: 10.1038/s41598-024-80051-8



100. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. *Proc Natl Acad Sci U S A*. (2010) 107:14298–303. doi: 10.1073/pnas.0914730107
101. Zeng C, Liu X, Zhu S, Xiong D, Zhu L, Hou X, et al. Resolvin D1 ameliorates hepatic steatosis by remodeling the gut microbiota and restoring the intestinal barrier integrity in DSS-induced chronic colitis. *Int Immunopharmacol*. (2022) 103:108500. doi: 10.1016/j.intimp.2021.108500
102. Li C, Zhao Y, Cheng J, Guo J, Zhang Q, Zhang X, et al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. *Adv Sci (Weinh)*. (2019) 6:1900610. doi: 10.1002/advs.201900610